Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Amikacin liposomal (Arikayce®) is recommended as an option for use within NHS Wales for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | amikacin liposomal (Arikayce®) | ||
| Formulation | 590 mg nebuliser dispersion | ||
| Reference number | 2140 | ||
| Indication | Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis |
||
| Company | Insmed Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1221 | ||
| NMG meeting date | 07/07/2021 | ||
| AWMSG meeting date | 14/09/2021 | ||
| Date of issue | 30/09/2021 | ||
| Commercial arrangement | WPAS | ||